Panelists discuss how decisions to switch between Bruton tyrosine kinase (BTK) inhibitors are driven by multiple factors including intolerable toxicities, development of resistance mutations ...
Credit: Nadezhda Fedrunova via Getty Images. AstraZeneca has received approval from the US Food and Drug Administration (FDA) for its Bruton’s tyrosine kinase (BTK) inhibitor, Calquence (acalabrutinib ...
AstraZeneca’s Calquence became the first BTK inhibitor approved in the US for first-line use in mantle cell lymphoma on Thursday. The drug ...
January 16, 2025—Concept Medical Inc., announced the enrollment of the first patient in the pivotal MAGICAL BTK randomized controlled trial, which is being conducted in the United States under an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback